Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…
Investigators sought to assess the effectiveness of SB5-adalimumab over 52 weeks in patients with Crohn disease after switching from originator-adalimumab.
Investigators assessed disparities in IBD clinical trials regarding a lack of inclusion of pregnant, lactating women; older adults; and racial and ethnic minorities.
Investigators examined whether a patient’s initial response to anti-tumor necrosis factor (TNF)-a antibody could inform subsequent treatment in ulcerative colitis.
Cosby A. Stone, MD, and Brigid S. Boland, MD, discuss the controversy of administering live vaccines to infants who were exposed to TNFi during pregnancy and breastfeeding.
Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis.
Researchers sought to identify the clinical factors of inflammatory bowel disease and celiac disease that are associated with receiving a positive stool GIPCR test.
Investigators analyzed adalimumab’s long-lasting clinical remission, associations of trough concentration, and linear growth in pediatric patients with Crohn disease.
A team of researchers assessed histologic activity in patients with ulcerative colitis who were in endoscopic and clinical remission, using the NHI score to predict future relapse.
Researchers assessed the association between simplified magnetic resonance index of activity and IC-measured inflammation levels in children with Crohn disease.
Researchers sought to create a histological index that would help evaluate inflammation and predict clinical outcomes in patients with ulcerative colitis.
A special issue of the Gastroenterology journal explores the future of treatment for inflammatory bowel diseases like Crohn disease and ulcerative colitis.